The company has secured 506 marketing approvals for its oncology products across 76 countries.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
This is the fourth facility from the company to receive this registration
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
The company also plans to register the similar range of products in the neighbouring countries.
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Subscribe To Our Newsletter & Stay Updated
